title: Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.
abstract: Clinical management of infective endocarditis (IE) is expected to become more difficult with the emergence of Staphylococcus aureus with reduced susceptibility to vancomycin (SARV) in the United States and worldwide. We report the strain characterization and treatment of a patient with SARV IE.
authors.affiliation: Clinical Microbiology, Durham Veterans Administration Medical Center, Durham, NC 27705, USA. woods004@mc.duke.edu
authors.forename: Christopher W
authors.initials: CW
authors.lastname: Woods
authors.forename: Allen C
authors.initials: AC
authors.lastname: Cheng
authors.forename: Vance G
authors.initials: VG
authors.lastname: Fowler
authors.forename: Mary
authors.initials: M
authors.lastname: Moorefield
authors.forename: Joyce
authors.initials: J
authors.lastname: Frederick
authors.forename: George
authors.initials: G
authors.lastname: Sakoulas
authors.forename: Venkata G
authors.initials: VG
authors.lastname: Meka
authors.forename: Fred C
authors.initials: FC
authors.lastname: Tenover
authors.forename: Peter
authors.initials: P
authors.lastname: Zwadyk
authors.forename: Kenneth H
authors.initials: KH
authors.lastname: Wilson
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects*; D017211:Treatment Failure; D014481:United States; D014640:Vancomycin / Q000494:pharmacology* / Q000627:therapeutic use; D020713:Vancomycin Resistance
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin